Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NativusWell is a branded, non‑hormonal nutraceutical tablet developed by Aptorum Group as a women’s health dietary supplement targeted to perimenopausal, menopausal and postmenopausal women.[1][13] The product consists of dioscorea opposita (Chinese yam) bioactive nutraceutical tablets containing a proprietary bioactive ingredient referred to as DOI, which has been reported by the company to exhibit anti‑ageing, antioxidant and bone‑supporting effects in preclinical research.[1][13] By leveraging yam‑derived DOI rather than exogenous estrogen, NativusWell is positioned as an alternative, non‑hormonal approach to support overall health and bone health in women experiencing symptoms associated with declining endogenous estrogen levels during the menopausal transition.[1][2][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NativusWell.